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of 27), there was no anatomic evidence of any cardiac disease other
than amyloidosis (1). That study also suggested that the V122I
allele was always associated with some degree of anatomic ventric-
ular amyloid in African Americans 60 years or older and is
consistent with the notion that age-dependent, autosomal domi-
nant cardiac amyloidosis could contribute to congestive failure.
Thus, if the BEST participants were representative of all
African Americans age 60 years or over with NYHA functional
class III and class IV CHF, late onset, autosomal dominant
cardiac amyloidosis due to the TTR V122I allele could be
responsible for 10% of severe heart failure in this population, a
possibility that should be investigated by a more formal study,
rather than as an add-on to a therapeutic trial.
Once considered, the diagnosis is possible by echocardiography
in the majority of cases and by endomyocardial biopsy in all
(subcutaneous fat aspiration might have a low diagnostic yield in
late onset cardiac deposition) (7,8). Although specific therapy is
not available at this time and liver transplantation is denied to
these individuals because of their age, the diagnosis suggests that
digoxin and calcium channel blockers might be avoided (9,10).
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Influence of Proteinuria on Cardiovascular Risk and Response to Angiotensin-Converting
Enzyme Inhibition After Myocardial Infarction
To the Editor: Proteinuria is a known predictor of cardiovascular
(CV) morbidity and mortality in diabetics, hypertensive patients,
and the general population (1–3), but the impact of proteinuria as
a risk factor after acute myocardial infarction (MI) is less well-
defined. We analyzed a subset of patients enrolled in the Survival
And Ventricular Enlargement (SAVE) trial in whom dipstick
urinalyses were recorded to determine the prognostic importance
of baseline proteinuria on outcomes, and to evaluate whether the
response to angiotensin-converting enzyme (ACE) inhibition is
affected by the presence of proteinuria.
The SAVE trial was a randomized, double-blind, placebo-
controlled trial examining the use of ACE inhibition in 2,231 patients
with acute MI and left ventricular dysfunction (left ventricular ejection
fraction [LVEF] 40%) (4). Patients with serum creatinine 2.5
mg/dl were randomized to captopril (50 mg three times a day) or
placebo on average 10 days post-MI. A total of 658 patients from the
Canadian cohort underwent dipstick urinalyses because of safety
concerns, and baseline dipstick measures were available in 583
patients. Dipstick classification included none, trace, 1, 2, 3,
4, corresponding to protein concentrations of10 mg/dl, 10 to 30,
30 to 100, 100 to 300, and 1,000 mg/dl, respectively (5). The
four-variable Modification of Diet in Renal Disease equation was
used to estimate glomerular filtration rate (eGFR) (6). Univariate and
multivariate estimates of risk for outcomes were derived using Cox
proportional hazards models, and the interaction between proteinuria
and treatment effect was assessed. All-cause mortality, CV mortality,
and a composite outcome of death, stroke, recurrent MI, and
hospitalization for congestive heart failure over 42 months of
follow-up were primary end points.
Of 583 subjects, 122 (20.9%) had trace or greater proteinuria
(trace, 14.9%; greater-than-trace, 6.0%). Proteinuric subjects were
older, more often hypertensive (p  0.03), with higher baseline
serum creatinine (p  0.001) Killip class (p  0.001), and lower
LVEF (p  0.001). Diabetes prevalence (p  0.18), use of
lipid-lowering agents (p  0.21), or use of aspirin (p  0.90) did
not significantly differ between patients groups. Proteinuria in-
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creased with decreasing eGFR, with lower eGFR in proteinuric
subjects (60.9 vs. 69.9 ml/min/1.73 m2, p  0.001).
Proteinuria was an independent predictor of all-cause mortality
(hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.20 to
2.82), CV mortality (HR 1.87, 95% CI 1.18 to 2.98), and the
composite end point (HR 1.41, 95% CI 0.99 to 2.02) after
adjusting for known covariates including age, gender, previous MI,
history of hypertension, history of diabetes, history of congestive
heart failure, body mass index, systolic/diastolic blood pressure,
LVEF, baseline eGFR, use of diuretics, and treatment assignment.
The combination of an eGFR 60 ml/min/1.73 m2 and protein-
uria conferred nearly a three-fold increased risk of death (HR 2.74,
95% CI 1.68 to 4.45) compared to having neither risk factor.
Mortality in patients with no, trace, or greater than trace protein-
uria was 20.0%, 25.3%, and 45.7%, respectively (p trend  0.002).
Subjects with proteinuria appeared to have the greatest reduc-
tion in all-cause and CV mortality with captopril therapy, with a
significant interaction between proteinuria and treatment assign-
ment (p  0.02) (Fig. 1). Captopril provided a greater mortality
benefit in patients with proteinuria (HR 0.46, 95% CI 0.24 to
0.89) compared to patients without (HR 0.83, 95% CI 0.55 to
1.25). A similar reduction in risk was seen for the composite end
point (proteinuria: HR 0.41, 95% CI 0.21 to 0.73; no proteinuria:
HR 0.87, 95% CI 0.63 to 1.19).
Proteinuria measured by standard urine dipstick at baseline in
patients with acute MI and systolic dysfunction was associated
with an increased risk for all-cause and CV mortality in patients
after MI with left ventricular dysfunction. Moreover, proteinuria
modified the benefit of captopril therapy.
That common dipstick urinalysis is such a potent predictor of
mortality reinforces the importance of proteinuria as a risk factor
for CV disease. Proteinuria, and specifically albuminuria, may
reflect early inflammation accompanying coronary artery disease
and MI. C-reactive protein and white blood cell counts are
increased in patients with albuminuria, suggesting that inflamma-
tion plays a role in glomerular and renal damage (7,8). Albumin-
uria is also associated with elevations of neurohormonal markers in
heart failure (9).
We previously showed that eGFR independently predicted CV
risk in the overall SAVE cohort (10). In this analysis, proteinuria
was associated with increased mortality irrespective of eGFR, with
the combination showing additive increased mortality. Whether
these risk factors influence outcomes by the same or separate
mechanisms requires further study.
Post-MI subjects with trace or higher proteinuria derived the
greatest absolute benefit from captopril treatment. The added
benefit seen in proteinuric patients most likely reflects the in-
creased risk observed in this population. It is important to note
that dipstick urinalysis provides only a crude estimate of protein
excretion, and may not be as accurate an indicator of CV risk as
tests with a higher sensitivity and specificity for quantifying
microalbuminuria. Although hypothesis-generating, proteinuria
may define a subgroup of patients who are more sensitive to the
protective effects of captopril.
In summary, we observed that proteinuria, measured with
dipstick urinalysis at baseline in patients with systolic dysfunction
post-MI, is predictive of all-cause and CV mortality, indepen-
dently of baseline renal function, as assessed by eGFR. The
benefit of captopril in reducing CV morbidity and mortality was
greatest in patients with proteinuria, suggesting that this
measure may help identify a group of patients who are at higher
risk, and who may receive additional benefit from ACE
inhibitor therapy after acute MI.
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Figure 1. Kaplan-Meier curves for the composite end point stratified by presence of proteinuria (P) and treatment assignment (placebo vs. captopril).
MI  myocardial infarction.
1726 Correspondence JACC Vol. 47, No. 8, 2006
April 18, 2006:1724–38
*Brigham and Women’s Hospital
75 Francis Street
Boston, Massachusetts 02115
E-mail: ssolomon@rics.bwh.harvard.edu
doi:10.1016/j.jacc.2006.01.047
Please note: the SAVE trial was originally supported by a grant from Bristol-Myers
Squibb. Mr. Jose was a research fellow supported by the Stanley J. Sarnoff
Endowment for Cardiovascular Science Inc.
REFERENCES
1. Gerstein HC, Mann JF, Yi Q, et al., HOPE Study Investigators.
Albuminuria and risk of cardiovascular events, death, and heart failure
in diabetic and nondiabetic individuals. JAMA 2001;286:421–6.
2. Berton G, Cordiano R, Mbaso S, De Toni R, Mormino P, Palatini P.
Prognostic significance of hypertension and albuminuria for early
mortality after acute myocardial infarction. J Hypertens 1998;16:525–
30.
3. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Protein-
uria as a risk factor for cardiovascular disease and mortality in older
people: a prospective study. Am J Med 2000;109:1–8.
4. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on
mortality and morbidity in patients with left ventricular dysfunction
after myocardial infarction. Results of the Survival And Ventricular
Enlargement trial. The SAVE Investigators. N Engl J Med
1992;327:669–77.
5. Laffeyette RA, Perrone RD, Levey AS. Laboratory evaluation of renal
function. In: Schrier RW, Gottschalk CW, editors. Diseases of the
Kidney. Boston, MA: Little Brown, 1996:339.
6. National Kidney Foundation Kidney Disease Outcome Quality Initiative
Advisory Board. K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Kidney Disease Out-
come Quality Initiative. Am J Kidney Dis 2002;39:S1–266.
7. Tong PC, Lee KF, So WY, et al. White blood cell count is associated
with macro- and microvascular complications in Chinese patients with
type 2 diabetes. Diabetes Care 2004;27:216–22.
8. Barzilay JI, Peterson D, Cushman M, et al. The relationship of
cardiovascular risk factors to microalbuminuria in older adults with or
without diabetes mellitus or hypertension: the cardiovascular health
study. Am J Kidney Dis 2004;44:25–34.
9. Berton G, Cordiano R, Palmieri R, Cucchini F, De Toni R, Palatini
P. Microalbuminuria during acute myocardial infarction; a strong
predictor for 1-year mortality. Eur Heart J 2001;22:1466–75.
10. Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease,
cardiovascular risk, and response to angiotensin-converting enzyme
inhibition after myocardial infarction: the Survival And Ventricular
Enlargement (SAVE) study. Circulation 2004;110:3667–73.
Intracoronary Delivery of Hematopoietic Bone Marrow Stem Cells and Luminal Loss of the
Infarct-Related Artery in Patients With Recent Myocardial Infarction
To the Editor: Angiogenesis and atherogenesis share a number of
pathways suggesting that interrelated tradeoffs might be inherent
to therapies designed to enhance collateral formation and cardiac
repair (1). This “Janus-like” effect on atherosclerosis progression
was observed in several experimental models exposed to therapy
with bone marrow stem cells (BMSCs) (1–4). A recent clinical
study reported high rates of in-stent restenosis after BMSC
mobilization (5). In our study (6), CD133 enriched BMSC
exerted beneficial effects on cardiac recovery in patients with
reperfused myocardial infarction, but the restenosis rates were also
higher as expected after intracoronary BMSC therapy (7–11).
Hence, we investigated the effects of intracoronary CD133
enriched BMSC on in-stent neointimal proliferation and distal
atherosclerosis progression in patients with recent myocardial
infarction treated with angioplasty using bare-metal stents.
Thirty-eight patients with acute myocardial infarction due to
occlusion of the proximal left anterior descending coronary artery
(LAD) were studied. The cell group consisted of 21 patients
receiving intracoronary injection of CD133 enriched BMSC and
follow-up catheterization with quantitative coronary angiography
(QCA) and coronary functional assessment with the pressure-
derived fractional flow reserve (FFR) (12,13). The control group
consisted of 17 patients matched for ejection fraction, infarction
size, and location with control catheterization between 4 and 8
months after the infarction. Segmental QCA analysis was per-
formed for the stented segment and non-stented portion of the
mid LAD and distal LAD. Data are shown as mean  SEM.
Paired t test and unpaired t test were used as appropriate.
There were no differences in clinical and demographic charac-
teristics between groups (not shown). Baseline angiographic and
functional characteristics are shown in Table 1. At follow-up, no
significant changes were noted in luminal diameters of the con-
tralateral artery (CLA) of either group (from 2.66  0.09 mm to
2.65  0.10 mm in the cell group, and from 2.71  0.14 mm to
2.78  0.17 mm in the control group, both p  NS). In contrast,
higher loss index of the stented segment in the cell group (0.42 
0.07 vs. 0.22  0.06, p  0.05) was paralleled by a greater
leftward shift in the cumulative distribution of the minimal
luminal diameter (MLD) as compared with the control group (Fig.
1A). In non-stented segments, cumulative luminal loss of the
reference diameter (RD) and MLD at the mid and distal segment
of the infarct-related artery (IRA) were higher in the cell group
Table 1. Baseline Angiographic Characteristics After Stented
Angioplasty Before Cell Injection
CD 133
(n  21)
Control
Subjects
(n  17) p Value
IRA—after stenting
RD stent (mm) 3.24  0.08 3.32  0.09 NS
MLD stent (mm) 2.84  0.10 2.93  0.12 NS
Nominal stent
diameter (mm)
3.25  0.07 3.31  0.08 NS
Nominal stent
length (mm)
21.8  1.5 25.5  2.6 NS
Distal IRA
RD mid segment (mm) 2.69  0.13 2.81  0.11 NS
MLD mid segment (mm) 2.21  0.11 2.31  0.15 NS
RD distal segment (mm) 2.03  0.08 2.38  0.11 0.05
MLD distal
segment (mm)
1.70  0.07 2.06  0.11 0.05
FFR IRA 0.86  0.02 0.83  0.02 NS
CLA
RD (mm) 2.66  0.09 2.71  0.14 NS
MLD (mm) 2.22  0.11 2.24  0.16 NS
FFR CLA 0.89  0.02 0.94  0.02 NS
CLA  contralateral artery; DS  diameter stenosis; FFR  fractional flow reserve;
IRA  infarct-related artery; MLD  minimal luminal diameter; RD  reference
diameter.
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